Janus Henderson Group PLC Takes $845,000 Position in Candel Therapeutics, Inc. $CADL

Janus Henderson Group PLC purchased a new position in shares of Candel Therapeutics, Inc. (NASDAQ:CADL) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 171,978 shares of the company’s stock, valued at approximately $845,000.

A number of other large investors have also modified their holdings of CADL. Vanguard Group Inc. boosted its stake in Candel Therapeutics by 12.3% during the 3rd quarter. Vanguard Group Inc. now owns 2,007,112 shares of the company’s stock valued at $10,236,000 after purchasing an additional 219,563 shares during the period. Geode Capital Management LLC raised its holdings in shares of Candel Therapeutics by 31.5% during the second quarter. Geode Capital Management LLC now owns 903,970 shares of the company’s stock valued at $4,575,000 after buying an additional 216,509 shares during the last quarter. Halter Ferguson Financial Inc. raised its holdings in shares of Candel Therapeutics by 20.9% during the first quarter. Halter Ferguson Financial Inc. now owns 904,051 shares of the company’s stock valued at $4,430,000 after buying an additional 155,996 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Candel Therapeutics during the third quarter worth approximately $697,000. Finally, State Street Corp grew its holdings in Candel Therapeutics by 15.0% in the 4th quarter. State Street Corp now owns 792,218 shares of the company’s stock worth $4,476,000 after buying an additional 103,452 shares in the last quarter. Institutional investors and hedge funds own 13.93% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on CADL shares. Wall Street Zen upgraded Candel Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Zacks Research raised Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. HC Wainwright reissued a “buy” rating and set a $23.00 price target on shares of Candel Therapeutics in a report on Wednesday, July 29th. Stifel Nicolaus began coverage on shares of Candel Therapeutics in a research note on Monday, July 13th. They set a “buy” rating and a $22.00 price objective on the stock. Finally, Cantor Fitzgerald started coverage on shares of Candel Therapeutics in a report on Monday, April 20th. They issued an “overweight” rating for the company. Seven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.57.

Insiders Place Their Bets

In related news, insider Francesca Barone sold 23,447 shares of Candel Therapeutics stock in a transaction on Monday, June 29th. The stock was sold at an average price of $10.06, for a total value of $235,876.82. Following the transaction, the insider directly owned 77,362 shares in the company, valued at $778,261.72. The trade was a 23.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CTO Seshu Tyagarajan sold 7,000 shares of the business’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $10.02, for a total value of $70,140.00. Following the sale, the chief technology officer directly owned 83,865 shares in the company, valued at $840,327.30. This trade represents a 7.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 14.30% of the stock is currently owned by corporate insiders.

Candel Therapeutics Stock Performance

Shares of CADL opened at $10.50 on Tuesday. Candel Therapeutics, Inc. has a 12-month low of $4.35 and a 12-month high of $11.36. The stock has a market capitalization of $769.34 million, a P/E ratio of -10.71 and a beta of -0.51. The firm’s 50 day moving average is $9.48 and its 200-day moving average is $7.27. The company has a debt-to-equity ratio of 0.34, a current ratio of 28.05 and a quick ratio of 28.05.

Candel Therapeutics (NASDAQ:CADL) last issued its earnings results on Thursday, May 14th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.16. Equities research analysts anticipate that Candel Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.

Candel Therapeutics Profile

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.